Prostate Cancer Trial, Recruiting (NCT06303622)

Prostate Cancer Trial, Recruiting NCT06303622 Sponsor: Chinese University of Hong Kong Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06303622 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Men aged 18 or older
People whose doctor suspects they may have prostate cancer and has recommended a prostate biopsy
People whose prostate-specific antigen (PSA) blood test result is below 20 ng/mL (a measure used to help detect prostate issues)
People whose rectal examination suggests the cancer, if present, appears to be contained within the prostate gland
People who are able to give written consent to participate
People whose MRI scan of the prostate shows between 1 and 3 areas of concern, rated on a standard scoring scale (PI-RADS) between 3 and 5

Who may not be able to join:

People who have had a prostate biopsy within the last 2 years
People who have already been diagnosed with prostate cancer
People for whom a prostate biopsy would be considered unsafe, such as those with an active urinary tract infection, certain physical conditions that prevent the procedure, uncorrectable blood clotting problems, or those taking blood-thinning medications that cannot be safely stopped beforehand (confirm with trial site)
People who do not wish to have a biopsy

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 13 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Peter Ka-Fungq CHIU, Chinese University of Hong Kong

Phone: 35052625

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06303622

Sponsor: Chinese University of Hong Kong

Phase: Not Applicable

Status: Recruiting

Condition: Prostate Cancer

Trial contact: 35052625

More information: https://clinicaltrials.gov/study/NCT06303622

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Men aged 18 or older
People whose doctor suspects they may have prostate cancer and has recommended a prostate biopsy
People whose prostate-specific antigen (PSA) blood test result is below 20 ng/mL (a measure used to help detect prostate issues)
People whose rectal examination suggests the cancer, if present, appears to be contained within the prostate gland
People who are able to give written consent to participate
People whose MRI scan of the prostate shows between 1 and 3 areas of concern, rated on a standard scoring scale (PI-RADS) between 3 and 5

Who may not be able to join:

People who have had a prostate biopsy within the last 2 years
People who have already been diagnosed with prostate cancer
People for whom a prostate biopsy would be considered unsafe, such as those with an active urinary tract infection, certain physical conditions that prevent the procedure, uncorrectable blood clotting problems, or those taking blood-thinning medications that cannot be safely stopped beforehand (confirm with trial site)
People who do not wish to have a biopsy

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 13 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Chinese University of Hong Kong

Registry

ClinicalTrials.gov

Start date

8 January 2025

Est. completion

31 December 2026

Where this trial is recruiting

Hong Kong

Primary endpoints

Proportion of men with clinically significant Prostate cancer(csPCa)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov